Updated:
ProQR Therapeutics
Daniel de Boer's ProQR blends RNA base editing with asset monetization, secured by a 2021 Eli Lilly partnership.
ProQR Therapeutics
Founded in 2012 by Daniel de Boer and Gerard Platenburg in Leiden, the Netherlands, ProQR Therapeutics focuses on rare genetic diseases through proprietary RNA-editing platforms. The company went public on Nasdaq in 2014, differentiating itself early with a pipeline targeting conditions like Leber congenital amaurosis 10 and cystic fibrosis. Its core scientific approach uses single-stranded oligonucleotides to repair genetic mutations at the RNA level, a strategy distinct from the DNA-editing focus of competitors like CRISPR Therapeutics. The firm's strategy blends biotech research with structured finance. ProQR's Axiomer platform enables RNA base editing, drawing a significant collaboration with Eli Lilly in 2021 that included a €20 million equity investment and up to $1.25 billion in milestones. Beyond development-stage assets, the company monetizes regulatory milestones — including the 2021 sale of a Rare Pediatric Disease Priority Review Voucher for $30 million. Its pipeline spans ophthalmology, liver, and central nervous system indications, with partnerships extending to Organon and the Cystic Fibrosis Foundation. Operations are centered in the Leiden Bio Science Park, one of Europe's largest life-science clusters. The company operated with 166 full-time employees as of its 2024 annual report and reported cash and equivalents of roughly €115 million at year-end 2024. Outside its core clinical programs, ProQR established a subsidiary, Amylon Therapeutics, targeting CNS disorders, which it later divested. In September 2023, the company announced a strategic pivot, discontinuing its sepofarsen and ultevursen ophthalmology programs after disappointing late-stage data, and refocusing resources on Axiomer and its AX-0810 program for cholestatic liver diseases. ProQR's structural differentiator sits in its dual identity: it is simultaneously a drug developer and a financial engineering entity. The firm repeatedly uses voucher sales and milestone securitization to fund research, reducing dilution risk in ways traditional biotechs typically cannot. This hybrid model — pairing a deep tech RNA platform with a disciplined asset-monetization function — creates a capital-efficiency profile uncommon among European clinical-stage companies.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
Europe
Country
Netherlands
City
Leiden
Corporate office
Leiden, Netherlands
Principals
Daniel de Boer
Founder and CEO
Gerard Platenburg
Founder and Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment decisions at ProQR Therapeutics?
ProQR operates as a clinical-stage biotech company, not an asset manager. Capital allocation decisions are made by CEO Daniel de Boer and the board, with the board's investment committee overseeing treasury and partnership economics. Major strategic moves, like the 2023 pipeline reprioritization, signal centralized decision-making under de Boer's leadership.
How is ProQR funded, and does it take outside LP capital?
ProQR is a Nasdaq-listed public company funded through equity offerings, pharmaceutical partnerships, and non-dilutive sources like priority review voucher sales. It does not raise discretionary funds from limited partners. The 2021 Eli Lilly collaboration brought €20 million in equity and up to $1.25 billion in milestones, alongside a separate €30 million voucher monetization that year.
What is the Axiomer platform, and how does it differ from CRISPR?
Axiomer is ProQR's RNA base-editing technology that uses synthetic guide oligonucleotides to recruit endogenous ADAR enzymes, converting adenosine to inosine at the RNA level. Unlike CRISPR, which makes permanent DNA cuts with attendant off-target risks, Axiomer edits are transient and reversible, operating on the transcriptome rather than the genome. Eli Lilly cited this safety profile as a key driver of its 2021 partnership.
Why did ProQR discontinue its lead ophthalmology programs in 2023?
ProQR's sepofarsen and ultevursen programs for inherited retinal diseases failed to meet primary endpoints in pivotal trials. In September 2023, the company announced a pipeline reprioritization, halting those programs and shifting resources toward the Axiomer platform and AX-0810, which targets cholestatic liver diseases. The move reflected both clinical setbacks and a strategic conviction that RNA editing represented a broader, more capital-efficient opportunity.
What is ProQR's relationship with Eli Lilly?
In 2021, Eli Lilly invested €20 million in ProQR equity and committed up to $1.25 billion in milestone payments as part of an exclusive collaboration to develop Axiomer-based therapies for liver and nervous system targets. Lilly gains access to ProQR's RNA-editing IP for up to five programs, while ProQR retains rights to clinical candidates in its core ophthalmology portfolio. The deal positions Lilly as the primary validator of the Axiomer platform.
Does ProQR maintain any philanthropic structures or patient-access programs?
ProQR has not established a separate philanthropic foundation, but its corporate structure includes expanded access and early-access programs for patients with severe genetic diseases who cannot enroll in clinical trials. The firm's Cystic Fibrosis Foundation partnership also carries a mission-aligned component, reflecting the foundation's venture-philanthropy model that funds therapeutics for underserved patient populations.
What is ProQR's known posture on co-investments alongside external GPs?
ProQR does not operate as a GP or LP in traditional fund structures. Its external partnerships are structured as pharmaceutical collaborations with milestone economics — not co-investment vehicles. Entities like Eli Lilly and the Cystic Fibrosis Foundation participate via direct program-level agreements rather than pooled capital, a model that aligns each partner's economics with specific clinical assets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: